Stalled at first jab: Vaccine shortages hit poor countries

News

Stalled at first jab: Vaccine shortages hit poor countries

FILE - In this April 8, 2021, file photo, a woman at Kenyatta National Hospital in Nairobi, Kenya, receives a dose of AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India and provided through the global COVAX initiative. COVAX is providing vaccines to countries lacking the clout to negotiate on their own for scarce supplies, but in the past two weeks only 2 million doses have been cleared for shipment to 92 countries. (AP Photo/Brian Inganga, File)
FILE - In this Feb. 25, 2021, file photo, a shipment of COVID-19 vaccines distributed by the COVAX global initiative arrives in Abidjan, Ivory Coast. As many as 60 countries, including some of the poorest, might be stalled at the first shots of their coronavirus vaccinations because nearly all deliveries through the program intended to help them are being blocked until as late as June. (AP Photo/Diomande Ble Blonde, File)
FILE - In this March 9, 2021, file photo, nurse Joseph Kenga prepares to administer an AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India and provided through the global COVAX initiative, to a health worker at the Coast General Teaching & Referral Hospital in Mombasa, Kenya. As many as 60 countries, including some of the poorest, might be stalled at the first shots of their vaccinations because nearly all deliveries through the global program intended to help them are being delayed. (AP Photo/Gideon Maundu, File)
FILE - In this March 5, 2021, file photo, a hospital security guard receives one of Kenya's first AstraZeneca COVID-19 vaccinations provided through the global COVAX initiative, at Kenyatta National Hospital in Nairobi. While COVAX is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, it has only cleared 2 million doses in the past two weeks because nearly all deliveries through the global program are blocked until as late as June. (AP Photo/Ben Curtis, File)
FILE - In this Feb. 7, 2021, file photo, boxes of the first shipment of 500,000 doses of the AstraZeneca coronavirus vaccine made by Serum Institute of India, donated by the Indian government, await distribution at the customs area of the Hamid Karzai International Airport, in Kabul, Afghanistan. A vaccine shortage stems mostly from India’s decision to stop exporting the vaccines from its Serum Institute factory, which produces the overwhelming majority of the AstraZeneca doses that the COVAX global initiative was counting on to supply to about a third of the world’s population. (AP Photo/Rahmat Gul, File)
FILE - In this March 15, 2021, file photo, boxes of AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India and provided through the COVAX global initiative arrive at the airport in Mogadishu, Somalia. COVAX is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but it has only cleared 2 million doses in the past two weeks because nearly all deliveries through the program are blocked until as late as June. On March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Farah Abdi Warsameh, File)
FILE - In this Jan. 21, 2021, file photo, Nepalese airport ground staffs pulls boxes of AstraZeneca vaccine, manufactured under license by Serum Institute of India, arrive at Tribhuwan International Airport in Kathmandu, Nepal. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but it has only cleared 2 million doses in the past two weeks because nearly all deliveries through the program are blocked until as late as June. On March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Niranjan Shrestha, File)
FILE - In this March 1, 2021, file photo, Youssouf Kouyate, National Police General Director, receives a shot of the AstraZeneca vaccine in Abidjan, Ivory Coast. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but on March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Diomande Ble Blonde, File)
FILE - In this March 3, 2021, file photo, AstraZeneca COVID-19 vaccines are received by airport workers at the airport in Kigali, Rwanda. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but on March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Muhizi Olivier, File)
FILE - In this March 3, 2021, file photo, the first arrival of COVID-19 vaccines to Kenya is offloaded from a Qatar Airways flight at Jomo Kenyatta International Airport in Nairobi, Kenya. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but on March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/File)

Stalled at first jab: Vaccine shortages hit poor countries

FILE - In this April 8, 2021, file photo, a woman at Kenyatta National Hospital in Nairobi, Kenya, receives a dose of AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India and provided through the global COVAX initiative. COVAX is providing vaccines to countries lacking the clout to negotiate on their own for scarce supplies, but in the past two weeks only 2 million doses have been cleared for shipment to 92 countries. (AP Photo/Brian Inganga, File)
FILE - In this Feb. 25, 2021, file photo, a shipment of COVID-19 vaccines distributed by the COVAX global initiative arrives in Abidjan, Ivory Coast. As many as 60 countries, including some of the poorest, might be stalled at the first shots of their coronavirus vaccinations because nearly all deliveries through the program intended to help them are being blocked until as late as June. (AP Photo/Diomande Ble Blonde, File)
FILE - In this March 9, 2021, file photo, nurse Joseph Kenga prepares to administer an AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India and provided through the global COVAX initiative, to a health worker at the Coast General Teaching & Referral Hospital in Mombasa, Kenya. As many as 60 countries, including some of the poorest, might be stalled at the first shots of their vaccinations because nearly all deliveries through the global program intended to help them are being delayed. (AP Photo/Gideon Maundu, File)
FILE - In this March 5, 2021, file photo, a hospital security guard receives one of Kenya's first AstraZeneca COVID-19 vaccinations provided through the global COVAX initiative, at Kenyatta National Hospital in Nairobi. While COVAX is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, it has only cleared 2 million doses in the past two weeks because nearly all deliveries through the global program are blocked until as late as June. (AP Photo/Ben Curtis, File)
FILE - In this Feb. 7, 2021, file photo, boxes of the first shipment of 500,000 doses of the AstraZeneca coronavirus vaccine made by Serum Institute of India, donated by the Indian government, await distribution at the customs area of the Hamid Karzai International Airport, in Kabul, Afghanistan. A vaccine shortage stems mostly from India’s decision to stop exporting the vaccines from its Serum Institute factory, which produces the overwhelming majority of the AstraZeneca doses that the COVAX global initiative was counting on to supply to about a third of the world’s population. (AP Photo/Rahmat Gul, File)
FILE - In this March 15, 2021, file photo, boxes of AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India and provided through the COVAX global initiative arrive at the airport in Mogadishu, Somalia. COVAX is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but it has only cleared 2 million doses in the past two weeks because nearly all deliveries through the program are blocked until as late as June. On March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Farah Abdi Warsameh, File)
FILE - In this Jan. 21, 2021, file photo, Nepalese airport ground staffs pulls boxes of AstraZeneca vaccine, manufactured under license by Serum Institute of India, arrive at Tribhuwan International Airport in Kathmandu, Nepal. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but it has only cleared 2 million doses in the past two weeks because nearly all deliveries through the program are blocked until as late as June. On March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Niranjan Shrestha, File)
FILE - In this March 1, 2021, file photo, Youssouf Kouyate, National Police General Director, receives a shot of the AstraZeneca vaccine in Abidjan, Ivory Coast. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but on March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Diomande Ble Blonde, File)
FILE - In this March 3, 2021, file photo, AstraZeneca COVID-19 vaccines are received by airport workers at the airport in Kigali, Rwanda. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but on March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/Muhizi Olivier, File)
FILE - In this March 3, 2021, file photo, the first arrival of COVID-19 vaccines to Kenya is offloaded from a Qatar Airways flight at Jomo Kenyatta International Airport in Nairobi, Kenya. The COVAX global initiative is providing vaccines to poorer countries lacking the clout to negotiate for them on their own, but on March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India had caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses. (AP Photo/File)